AlphAIalphai — Financial news for AI agents
medscape.comAUG 262 min read$BMY

Bristol Myers Ends Blood Cancer Drug Deal With Cell Therapy Maker Cellares

Bristol Myers Squibb (BMY) ended its partnership with Cellares to manufacture its blood cancer therapy, Breyanzi, citing commercial-scale production issues. Breyanzi generated $1.36B in 2025 sales. Cellares may lay off workers due to the loss. The 2024 deal was worth up to $380M.

Original reporting
medscape.com
Published Aug 26, 2026, 12:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 26, 2026, 1:10 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
$BMY
Bearish
high confidence
Mentioned
$BMY
Relevance
8/10
alphai data visualization · based on medscape.com
Decision brief

The 30-second read

$BMYBearishHigh
01

Why it matters

The deal termination signals operational challenges for BMS's Breyanzi product, which generated $1.36B in 2025 sales.

02

Market read

First report of partnership termination; material for BMY valuation and supply‑chain risk assessment.

03

What to watch

Cellares' capacity issues could affect other pharma partners, potentially creating opportunities for competitors.

Relevance 8/10Novelty 8/10Timing: today

Background

BMS had a 2024 agreement with Cellares worth up to $380M for CAR‑T manufacturing across multiple regions.

Company-level read

Ticker impact

$BMYBearishHigh confidence
Context

Bristol Myers Squibb ended its partnership with Cellares, terminating a $380M manufacturing deal for Breyanzi CAR‑T therapy.

Expected impact

Potential short‑term downside as investors reassess CAR‑T pipeline execution.

Evidence & confidence

The termination removes a key manufacturing partner, creating supply‑chain risk for a $1.36B revenue product.

Market effects

Sector

CAR‑T and broader oncology biotech sector may see heightened scrutiny on manufacturing partnerships.

Regional

U.S. biotech equities could face modest pressure as supply‑chain concerns emerge.

Global

Limited to companies with similar cell‑therapy manufacturing dependencies.

Counterpoint

What could challenge this read

The termination may allow BMS to partner with a more scalable manufacturer, improving long‑term margins.

Key entities

  • company
    Bristol Myers Squibb

    Large U.S. pharmaceutical company, ticker BMY.

  • company
    Cellares

    Cell‑therapy startup, private.

Read at source← All news

Related articles

AUG 21
$BMYMedAI 8/10

Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK

Bristol-Myers Squibb (BMY) will invest $2.3B in a Houston plant, part of a $40B U.S. investment. Eli Lilly (LLY) won UK approval for its weight-loss drug, Foundayo. BMY's investment aims to boost domestic manufacturing, while LLY expands internationally. Both companies face challenges, including patent expirations for BMY and market competition for LLY. Hedge funds show mixed interest in both stocks.

insidermonkey.com3 min
AUG 21
$BMYMedAI 8/10

Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

Bristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.

finance.yahoo.com3 min
AUG 21
$AZNMedAI 8/10

Fierce Pharma Asia—China's IIT scrutiny; Daiichi Sankyo, AZ ph. 3 win; Leo, Tanabe's dermatology deal

China's IIT system faces scrutiny after undisclosed gene therapy deaths. AstraZeneca and Daiichi Sankyo's Enhertu showed promise in lung cancer trials. Tanabe Pharma to receive $435M for global rights to dermatology drug. Sandoz partners with Shanghai Henlius for biosimilars. Other biotech news includes CAR-T trial deaths, SK's settlement, and Hengrui's profit squeeze.

fiercepharma.com3 min
AUG 18
$BMYMedAI 8/10

FDA Clears a New Class of Myeloma Drug for Patients Whose Cancer Returned After Earlier Treatment

The FDA granted accelerated approval to iberdomide (Zenbexus) for adults with relapsed or refractory multiple myeloma after at least one prior therapy, introducing the first CELMoD class drug in myeloma. The approval is based on the EXCALIBER-RRMM trial, where 41% vs 21% achieved MRD-negative complete response at 16 months. Iberdomide is combined with daratumumab (Darzalex Faspro) and dexamethasone.

medicaldaily.com6 min